Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report
Abstract Primary CNS lymphoma (PCNSL) is a highly aggressive malignant disease with a high recurrence rate and a poor prognosis. We present the case of a 71-year-old woman diagnosed with PCNSL in June 2010. After 3 relapses and intensive treatment with multiple chemotherapy regimens and whole-brain...
Gespeichert in:
| Veröffentlicht in: | Case Reports in Oncology 2021-09, Vol.14 (3), p.1337-1341 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1341 |
|---|---|
| container_issue | 3 |
| container_start_page | 1337 |
| container_title | Case Reports in Oncology |
| container_volume | 14 |
| creator | Mair, Anna Muigg, Armin Stockhammer, Günther Mangesius, Stephanie Wolf, Dominik Gunsilius, Eberhard |
| description | Abstract
Primary CNS lymphoma (PCNSL) is a highly aggressive malignant disease with a high recurrence rate and a poor prognosis. We present the case of a 71-year-old woman diagnosed with PCNSL in June 2010. After 3 relapses and intensive treatment with multiple chemotherapy regimens and whole-brain radiotherapy, she received off-label treatment with the Bruton tyrosine kinase inhibitor ibrutinib, responded well, achieved a complete remission, and is progression-free for now >3 years. |
| doi_str_mv | 10.1159/000518528 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000518528</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A688777346</galeid><doaj_id>oai_doaj_org_article_3040490ca9f848f79fd1e7f1fab3d383</doaj_id><sourcerecordid>A688777346</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4448-a87b15cb763ad9f2f2269d1c169f76115b0345cf151629920490aa6e7d9bfb1b3</originalsourceid><addsrcrecordid>eNptkk1v1DAQhiMEoqVw4M7BUk8ctthx_MUBaRVRWGlL0bacLTuxd70kcbAdqv33eEm1ohLyYax533k0o5mieIvgFUJEfIAQEsRJyZ8V54jSckEJI8__-Z8Vr2LcQ0gFoeRlcYYrVkKB-Xkx3U0xKTeYFtS-HzuTDNiY3sXo_ADcAG6mLrnFxnRqjNn0PbhehQOov92B9aEfd75X4D4YlbL44NIOrHSYkhucBjd-8GlnghoPH8ES1Coe2aMP6XXxwqoumjeP8aL4cf35vv66WN9-WdXL9aKpqoovFGcakUYzilUrbGnLkooWNYgKy2geXUNckcYigmgpRAkrAZWihrVCW400vihWM7f1ai_HuXfplZN_Ez5spQrJNZ2RGFbH8kYJyytumbAtMswiqzRuMceZ9WlmjZPuTduYIQXVPYE-VQa3k1v_W-bFkJLyDLh8BAT_azIxyb2fwpDnlyXNI3GSF5RdV7Nrq3JXbrA-w5r82ryVxg_GupxfUs4ZY7g6FryfC5rgYwzGnlpCUB7PQ57OI3vfzd6fKmxNODlP8uV_5XpzOzvk2Fr8B5NCwBc</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2616985006</pqid></control><display><type>article</type><title>Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Karger Open Access</source><source>PubMed Central</source><creator>Mair, Anna ; Muigg, Armin ; Stockhammer, Günther ; Mangesius, Stephanie ; Wolf, Dominik ; Gunsilius, Eberhard</creator><creatorcontrib>Mair, Anna ; Muigg, Armin ; Stockhammer, Günther ; Mangesius, Stephanie ; Wolf, Dominik ; Gunsilius, Eberhard</creatorcontrib><description>Abstract
Primary CNS lymphoma (PCNSL) is a highly aggressive malignant disease with a high recurrence rate and a poor prognosis. We present the case of a 71-year-old woman diagnosed with PCNSL in June 2010. After 3 relapses and intensive treatment with multiple chemotherapy regimens and whole-brain radiotherapy, she received off-label treatment with the Bruton tyrosine kinase inhibitor ibrutinib, responded well, achieved a complete remission, and is progression-free for now >3 years.</description><identifier>ISSN: 1662-6575</identifier><identifier>EISSN: 1662-6575</identifier><identifier>DOI: 10.1159/000518528</identifier><identifier>PMID: 34720938</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Biopsy ; Blood-brain barrier ; Cancer ; Cancer regression ; Cancer therapies ; Care and treatment ; Case Report ; Case reports ; Chemotherapy ; Diagnosis ; Drug dosages ; Health aspects ; ibrutinib ; Immunoglobulins ; Inhibitor drugs ; Lymphoma ; Medical prognosis ; Mutation ; Nervous system ; Non-Hodgkin's lymphomas ; Observations ; Patient outcomes ; Patients ; primary cns lymphoma ; Radiation therapy ; Remission (Medicine) ; Risk factors ; Stem cell transplantation ; Targeted cancer therapy ; Tomography</subject><ispartof>Case Reports in Oncology, 2021-09, Vol.14 (3), p.1337-1341</ispartof><rights>2021 The Author(s). Published by S. Karger AG, Basel</rights><rights>COPYRIGHT 2021 S. Karger AG</rights><rights>2021 The Author(s). Published by S. Karger AG, Basel . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at: https://uk.sagepub.com/en-gb/eur/reusing-open-access-and-sage-choice-content</rights><rights>Copyright © 2021 by S. Karger AG, Basel 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4448-a87b15cb763ad9f2f2269d1c169f76115b0345cf151629920490aa6e7d9bfb1b3</citedby><orcidid>0000-0001-5790-2724 ; 0000-0003-1327-2921</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525268/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525268/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,27635,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Mair, Anna</creatorcontrib><creatorcontrib>Muigg, Armin</creatorcontrib><creatorcontrib>Stockhammer, Günther</creatorcontrib><creatorcontrib>Mangesius, Stephanie</creatorcontrib><creatorcontrib>Wolf, Dominik</creatorcontrib><creatorcontrib>Gunsilius, Eberhard</creatorcontrib><title>Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report</title><title>Case Reports in Oncology</title><addtitle>Case Rep Oncol</addtitle><description>Abstract
Primary CNS lymphoma (PCNSL) is a highly aggressive malignant disease with a high recurrence rate and a poor prognosis. We present the case of a 71-year-old woman diagnosed with PCNSL in June 2010. After 3 relapses and intensive treatment with multiple chemotherapy regimens and whole-brain radiotherapy, she received off-label treatment with the Bruton tyrosine kinase inhibitor ibrutinib, responded well, achieved a complete remission, and is progression-free for now >3 years.</description><subject>Biopsy</subject><subject>Blood-brain barrier</subject><subject>Cancer</subject><subject>Cancer regression</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Case Report</subject><subject>Case reports</subject><subject>Chemotherapy</subject><subject>Diagnosis</subject><subject>Drug dosages</subject><subject>Health aspects</subject><subject>ibrutinib</subject><subject>Immunoglobulins</subject><subject>Inhibitor drugs</subject><subject>Lymphoma</subject><subject>Medical prognosis</subject><subject>Mutation</subject><subject>Nervous system</subject><subject>Non-Hodgkin's lymphomas</subject><subject>Observations</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>primary cns lymphoma</subject><subject>Radiation therapy</subject><subject>Remission (Medicine)</subject><subject>Risk factors</subject><subject>Stem cell transplantation</subject><subject>Targeted cancer therapy</subject><subject>Tomography</subject><issn>1662-6575</issn><issn>1662-6575</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DOA</sourceid><recordid>eNptkk1v1DAQhiMEoqVw4M7BUk8ctthx_MUBaRVRWGlL0bacLTuxd70kcbAdqv33eEm1ohLyYax533k0o5mieIvgFUJEfIAQEsRJyZ8V54jSckEJI8__-Z8Vr2LcQ0gFoeRlcYYrVkKB-Xkx3U0xKTeYFtS-HzuTDNiY3sXo_ADcAG6mLrnFxnRqjNn0PbhehQOov92B9aEfd75X4D4YlbL44NIOrHSYkhucBjd-8GlnghoPH8ES1Coe2aMP6XXxwqoumjeP8aL4cf35vv66WN9-WdXL9aKpqoovFGcakUYzilUrbGnLkooWNYgKy2geXUNckcYigmgpRAkrAZWihrVCW400vihWM7f1ai_HuXfplZN_Ez5spQrJNZ2RGFbH8kYJyytumbAtMswiqzRuMceZ9WlmjZPuTduYIQXVPYE-VQa3k1v_W-bFkJLyDLh8BAT_azIxyb2fwpDnlyXNI3GSF5RdV7Nrq3JXbrA-w5r82ryVxg_GupxfUs4ZY7g6FryfC5rgYwzGnlpCUB7PQ57OI3vfzd6fKmxNODlP8uV_5XpzOzvk2Fr8B5NCwBc</recordid><startdate>20210920</startdate><enddate>20210920</enddate><creator>Mair, Anna</creator><creator>Muigg, Armin</creator><creator>Stockhammer, Günther</creator><creator>Mangesius, Stephanie</creator><creator>Wolf, Dominik</creator><creator>Gunsilius, Eberhard</creator><general>S. Karger AG</general><general>Karger Publishers</general><scope>M--</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-5790-2724</orcidid><orcidid>https://orcid.org/0000-0003-1327-2921</orcidid></search><sort><creationdate>20210920</creationdate><title>Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report</title><author>Mair, Anna ; Muigg, Armin ; Stockhammer, Günther ; Mangesius, Stephanie ; Wolf, Dominik ; Gunsilius, Eberhard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4448-a87b15cb763ad9f2f2269d1c169f76115b0345cf151629920490aa6e7d9bfb1b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biopsy</topic><topic>Blood-brain barrier</topic><topic>Cancer</topic><topic>Cancer regression</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Case Report</topic><topic>Case reports</topic><topic>Chemotherapy</topic><topic>Diagnosis</topic><topic>Drug dosages</topic><topic>Health aspects</topic><topic>ibrutinib</topic><topic>Immunoglobulins</topic><topic>Inhibitor drugs</topic><topic>Lymphoma</topic><topic>Medical prognosis</topic><topic>Mutation</topic><topic>Nervous system</topic><topic>Non-Hodgkin's lymphomas</topic><topic>Observations</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>primary cns lymphoma</topic><topic>Radiation therapy</topic><topic>Remission (Medicine)</topic><topic>Risk factors</topic><topic>Stem cell transplantation</topic><topic>Targeted cancer therapy</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mair, Anna</creatorcontrib><creatorcontrib>Muigg, Armin</creatorcontrib><creatorcontrib>Stockhammer, Günther</creatorcontrib><creatorcontrib>Mangesius, Stephanie</creatorcontrib><creatorcontrib>Wolf, Dominik</creatorcontrib><creatorcontrib>Gunsilius, Eberhard</creatorcontrib><collection>Karger Open Access</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Case Reports in Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mair, Anna</au><au>Muigg, Armin</au><au>Stockhammer, Günther</au><au>Mangesius, Stephanie</au><au>Wolf, Dominik</au><au>Gunsilius, Eberhard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report</atitle><jtitle>Case Reports in Oncology</jtitle><addtitle>Case Rep Oncol</addtitle><date>2021-09-20</date><risdate>2021</risdate><volume>14</volume><issue>3</issue><spage>1337</spage><epage>1341</epage><pages>1337-1341</pages><issn>1662-6575</issn><eissn>1662-6575</eissn><abstract>Abstract
Primary CNS lymphoma (PCNSL) is a highly aggressive malignant disease with a high recurrence rate and a poor prognosis. We present the case of a 71-year-old woman diagnosed with PCNSL in June 2010. After 3 relapses and intensive treatment with multiple chemotherapy regimens and whole-brain radiotherapy, she received off-label treatment with the Bruton tyrosine kinase inhibitor ibrutinib, responded well, achieved a complete remission, and is progression-free for now >3 years.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>34720938</pmid><doi>10.1159/000518528</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-5790-2724</orcidid><orcidid>https://orcid.org/0000-0003-1327-2921</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1662-6575 |
| ispartof | Case Reports in Oncology, 2021-09, Vol.14 (3), p.1337-1341 |
| issn | 1662-6575 1662-6575 |
| language | eng |
| recordid | cdi_crossref_primary_10_1159_000518528 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Karger Open Access; PubMed Central |
| subjects | Biopsy Blood-brain barrier Cancer Cancer regression Cancer therapies Care and treatment Case Report Case reports Chemotherapy Diagnosis Drug dosages Health aspects ibrutinib Immunoglobulins Inhibitor drugs Lymphoma Medical prognosis Mutation Nervous system Non-Hodgkin's lymphomas Observations Patient outcomes Patients primary cns lymphoma Radiation therapy Remission (Medicine) Risk factors Stem cell transplantation Targeted cancer therapy Tomography |
| title | Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T04%3A35%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sustained%20Complete%20Remission%20in%20Multi-Relapsed%20Primary%20CNS%20Lymphoma%20Treated%20with%20Ibrutinib%20Monotherapy:%20A%20Case%20Report&rft.jtitle=Case%20Reports%20in%20Oncology&rft.au=Mair,%20Anna&rft.date=2021-09-20&rft.volume=14&rft.issue=3&rft.spage=1337&rft.epage=1341&rft.pages=1337-1341&rft.issn=1662-6575&rft.eissn=1662-6575&rft_id=info:doi/10.1159/000518528&rft_dat=%3Cgale_cross%3EA688777346%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2616985006&rft_id=info:pmid/34720938&rft_galeid=A688777346&rft_doaj_id=oai_doaj_org_article_3040490ca9f848f79fd1e7f1fab3d383&rfr_iscdi=true |